Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review
- 1Addiction Psychiatry Program, Department of Psychiatry Indiana University School of Medicine Indianapolis Indiana USA
Abstract
Background and Objectives: Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS. This paper explores accumulating literature describing Opioid Withdrawal Syndrome‐associated Cognitive Impairment (OWSCI) which may inform clinical care and therapeutics research.
Methods: A search of studies published before August 2026 was conducted via PubMed and Google Scholar (309 and 626 papers screened) via crossing “cognition” with “opioid withdrawal,” “early opioid abstinence,” “opioid use,” or “opioid addiction.” Bibliography searches were also conducted of core target papers defined as human adult studies measuring cognition during OWS from 1 to 15 days after last opioid use.
Results: Only seven studies were identified meeting core criteria. These varied considerably by design, patient samples, comorbidities, timing and methods of cognitive testing, and OWS treatments. The evidence thus far suggests OWSCI is a measurable transient feature of OWS that overlays, and is modulated by, a wide range of clinical variables including opioid history, medication treatments, other addictions, and neuropsychiatric comorbidities.
Discussion and Conclusions: Future studies on OWSCI entailing more rigorous experimental controls and standardizations, while accounting for diverse comorbidities and OWS treatments, are needed to more fully characterize OWSCI.
Scientific Significance: Growing data on OWSCI are deepening our understanding of neurobiological and clinical dimensions of OWS, potentially providing clues for improving treatments for patients transitioning through OWS into opioid‐free recoveries.
Related
- Sarcopenia and cognitive impairment after hip fracture in older adults: a narrative review and conceptual rehabilitation framework
- The Role of Herbal Medicines in Cognitive Impairment: A Narrative Review of Neuroprotective Mechanisms and Therapeutic Perspectives
- Negative Symptom Dimensions Link Cognitive Impairment to Global and Social Functioning in 22q11.2 Deletion Syndrome
- Multidisciplinary Perioperative and Post-Acute Care for Older Adults with Hip Fracture and Cognitive Impairment or Dementia: A Narrative Review.
- Neuropathic Pain Comorbid Cognitive Impairment and Vitamin D: A Narrative Review From Mechanisms to Clinical Management.
BibTeX
@article{khan2026opioid,
title = {{Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review}},
author = {Faizan Khan and Nazli Tunali and R. Andrew Chambers},
journal = {The American Journal on Addictions},
year = {2026},
month = sep,
doi = {10.1111/ajad.70201},
url = {https://doi.org/10.1111/ajad.70201},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review
AU - Faizan Khan
AU - Nazli Tunali
AU - R. Andrew Chambers
PY - 2026
DA - 2026/09/17
JO - The American Journal on Addictions
DO - 10.1111/ajad.70201
UR - https://doi.org/10.1111/ajad.70201
AB - Background and Objectives: Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS. This paper explores accumulating literature describing Opioid Withdrawal Syndrome‐associated Cognitive Impairment (OWSCI) which may inform clinical care and therapeutics research. Methods: A search of studies published before August 2026 was conducted via PubMed and Google Scholar (309 and 626 papers screened) via crossing “cognition” with “opioid withdrawal,” “early opioid abstinence,” “opioid use,” or “opioid addiction.” Bibliography searches were also conducted of core target papers defined as human adult studies measuring cognition during OWS from 1 to 15 days after last opioid use. Results: Only seven studies were identified meeting core criteria. These varied considerably by design, patient samples, comorbidities, timing and methods of cognitive testing, and OWS treatments. The evidence thus far suggests OWSCI is a measurable transient feature of OWS that overlays, and is modulated by, a wide range of clinical variables including opioid history, medication treatments, other addictions, and neuropsychiatric comorbidities. Discussion and Conclusions: Future studies on OWSCI entailing more rigorous experimental controls and standardizations, while accounting for diverse comorbidities and OWS treatments, are needed to more fully characterize OWSCI. Scientific Significance: Growing data on OWSCI are deepening our understanding of neurobiological and clinical dimensions of OWS, potentially providing clues for improving treatments for patients transitioning through OWS into opioid‐free recoveries.
SN - 1055-0496
SN - 1521-0391
ER -